Real-world treatment landscape and clinical outcomes in first-line advanced or metastatic gastroesophageal adenocarcinoma in the United States. (PubMed, Oncologist) - Sep 10, 2026 - "IO+FOLFOX/CAPOX was the most frequent first-line regimen in advanced or metastatic GC/GEJC/EAC and showed improved real-world outcomes versus FOLFOX/CAPOX. Despite these gains, overall survival remains poor, underscoring unmet needs and the importance of biomarker-informed treatment selection."
Clinical data • HEOR • IO biomarker • Journal • Real-world evidence • Esophageal Adenocarcinoma • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor • HER-2 • PD-L1
|
|
Daniel O Koralek; Jaffer A Ajani; Jin Gu; Ravindra Gupta; Shivani K Mhatre
|